Immunology: Current Research
Open Access

PD-1; CTLA-4; Immune checkpoint inhibitors; Cancer immunotherapy; Synergistic therapy; Immune-related adverse events (irAEs); Tumor resistance.

Introduction

Cancer immunotherapy has dramatically altered the therapeutic landscape for a range of malignancies. Central to this shift are immune checkpoint inhibitors (ICIs), which work by targeting inhibitory signals that prevent effective immune responses against tumors. Among the most prominent immune checkpoints are programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), both of which are critical in regulating T-cell responses [1]. PD-1 is a receptor found on the surface of T-cells that, when bound by its ligands (PD-L1 and PD-L2), suppresses T-cell activation. Similarly, CTLA-4, expressed on T-cells, negatively regulates immune activation by binding to CD80/CD86 on antigen-presenting cells. By inhibiting PD-1 and CTLA-4, immune checkpoints are blocked, leading to enhanced T-cell-mediated immune responses against tumor cells. The success of PD-1 inhibitors like pembrolizumab and nivolumab, and CTLA-4 inhibitors such as ipilimumab, has paved the way for these therapies in clinical oncology [2]. PD-1 inhibitors have demonstrated clinical efficacy across various tumor types, including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma. Meanwhile, CTLA-4 inhibitors, especially in combination with PD-1 inhibitors, have also shown promise in enhancing anti-tumor immunity [3]. Despite their success, the use of ICIs is not without limitations. Resistance to therapy, the occurrence of immune-related adverse events (irAEs), and the challenge of identifying optimal biomarkers for patient selection remain significant hurdles. Moreover, while monotherapies have shown benefits, the combination of PD-1 and CTLA-4 inhibitors offers the potential for synergistic effects, improving overall treatment efficacy [4]. This combination strategy has been a subject of extensive research, yielding valuable insights into its potential to overcome some of the challenges associated with ICI therapies. This review examines the current status of PD-1 and CTLA-4 inhibitors in cancer therapy, highlights recent advances, and discusses future directions to improve their effectiveness and mitigate associated risks [5].

Results

Clinical trials evaluating PD-1 and CTLA-4 inhibitors have demonstrated significant improvements in survival outcomes for patients with various cancers. Pembrolizumab and nivolumab, two PD-1 inhibitors, have shown durable responses and improved overall survival in cancers such as melanoma, NSCLC, and head and neck squamous cell carcinoma. Similarly, the CTLA-4 inhibitor ipilimumab has achieved success in melanoma, with notable improvements in progression-free survival and overall survival. Combination therapies utilizing both PD-1 and CTLA-4 inhibitors have shown synergistic effects, especially in melanoma. The combination of nivolumab and ipilimumab has led to higher response rates and prolonged survival compared to monotherapies, though it is associated with an increased risk of immune-related adverse events (irAEs). Other combination strategies, such as PD-1 inhibitors with other immunotherapies or targeted agents, are also being explored. Emerging studies indicate that biomarkers such as PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) could predict response to PD-1/CTLA-4 inhibition. However, the identification of reliable biomarkers remains an area of active research, as the current markers are not universally predictive. Resistance mechanisms, including the upregulation of alternative immune checkpoints or lack of antigen presentation, also contribute to therapy failure. Ongoing clinical trials are investigating approaches to overcome these resistance mechanisms, such as combining ICIs with other modalities like chemotherapy, radiation, or targeted therapies.

Discussion

While immune checkpoint inhibitors targeting PD-1 and CTLA-4 have revolutionized cancer treatment, there are several challenges to overcome. One of the key hurdles is patient selection. Not all patients respond to ICIs, and current biomarkers such as PD-L1 expression have limited predictive value [6]. Tumor heterogeneity, which may influence the immune microenvironment, complicates the identification of ideal candidates for ICI therapies. This has led to the search for additional biomarkers, including tumor mutational burden (TMB) and microsatellite instability (MSI), which are being studied as potential predictors of response. Moreover, while the combination of PD-1 and CTLA-4 inhibitors has shown promising results, it is associated with a higher risk of immune-related adverse events (irAEs). These include autoimmune conditions like colitis, pneumonitis, and dermatitis, which can severely impact the quality of life and limit the use of these therapies in certain patients. Balancing efficacy with safety remains a critical challenge, as optimal dosing schedules and strategies to manage irAEs are still being refined. Another significant issue is resistance to therapy [7]. Despite initial responses, many patients eventually experience disease progression. Mechanisms of resistance include the upregulation of other immune checkpoints, lack of tumor antigen presentation, and the suppression of immune cells by the tumor microenvironment. Novel strategies to overcome resistance, such as combining ICIs with other therapies, including targeted therapies and oncolytic viruses, are being actively investigated. Finally, the economic burden of these therapies, due to high costs and the need for prolonged treatment, poses challenges for widespread adoption and accessibility, particularly in low-resource settings [8].

Conclusion

In conclusion, PD-1 and CTLA-4 inhibitors have significantly transformed cancer immunotherapy, offering new hope for patients with previously difficult-to-treat cancers. Monotherapies with PD-1 and CTLA-4 inhibitors have demonstrated considerable efficacy, with PD-1 inhibitors showing substantial survival benefits across multiple cancer types. The combination of PD-1 and CTLA-4 inhibitors has also yielded promising results, particularly in melanoma, though it is associated with increased immune-related adverse events (irAEs). Despite their clinical success, several challenges persist. Resistance to therapy remains a significant issue, with some patients failing to respond to treatment or experiencing progression after initial benefits. Identifying reliable biomarkers to predict patient response and guide treatment decisions is crucial for improving the efficacy and precision of immune checkpoint inhibition. Furthermore, while the combination of PD-1 and CTLA-4 inhibitors holds great promise, the heightened risk of irAEs requires careful management and patient monitoring. The future of PD-1 and CTLA-4 inhibition lies in optimizing combination therapies, developing new strategies to overcome resistance, and improving the identification of patients who are most likely to benefit from treatment. Ongoing research is also focused on minimizing the toxicity of these therapies through personalized approaches and finding innovative ways to manage adverse effects. Additionally, the economic burden associated with these therapies must be addressed to ensure equitable access to these potentially life-saving treatments. As research progresses, the landscape of immune checkpoint inhibition will continue to evolve, offering new opportunities for cancer patients worldwide.

Acknowledgment

None

Conflict of Interest

None

References

1. Ni L, Dong C (2017) New checkpoints in cancer immunotherapy. Immunol rev 276: 52-65.

Indexed at, Google Scholar, Crossref

2. Widodo SS, Hutchinson RA, Fang Y, Mangiola S, Neeson PJ, et al. (2021) Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment. Cancer Immunol Immunother 70: 1811-1820.

Indexed at, Google Scholar, Crossref

3. Topalian SL (2017) Targeting immune checkpoints in cancer therapy. Jama 318: 1647-1648.

Indexed at, Google Scholar, Crossref

4. Lee L, Gupta M, Sahasranaman S (2016) Immune Checkpoint inhibitors: An introduction to the next‐generation cancer immunotherapy. J Clin Pharmacol 56: 157-169.

Indexed at, Google Scholar, Crossref

5. Sadreddini S, Baradaran B, Aghebati‐Maleki A, Sadreddini S, Shanehbandi D, et al. (2019) Immune checkpoint blockade opens a new way to cancer immunotherapy. J cell physiol 234: 8541-8549.

Indexed at, Google Scholar, Crossref

6. Obradovic A (2023) Precision immunotherapy. Science 379: 654-655.

Indexed at, Google Scholar, Crossref

7. Swatler J, Kozłowska E (2016) Immune checkpoint‑targeted cancer immunotherapies. Postepy Hig Med Dosw 70: 25-42.

Indexed at, Google Scholar, Crossref

8. Paucek RD, Baltimore D, Li G (2019) The cellular immunotherapy revolution: arming the immune system for precision therapy. Trends immunol 40: 292-309.

Indexed at, Google Scholar, Crossref